APO Research
Talk to an analyst

APO RESEARCH · REPORT

Lung Cancer Screening Software

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Lung Cancer Screening Software Market Outlook and Growth Opportunities 2026

22 January 2026197 pages

Choose your research edition.

Industry ResearchLung Cancer Screening Software Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Lung Cancer Screening Software Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Lung Cancer Screening Software Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Lung Cancer Screening Software Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Lung Cancer Screening Software Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Lung Cancer Screening Software market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Lung Cancer Screening Software is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Lung Cancer Screening Software is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Lung Cancer Screening Software is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Lung Cancer Screening Software market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Lung Cancer Screening Software market include Siemens Healthineers, GE HealthCare, Philips Healthcare, Canon Medical Systems, United Imaging Healthcare, InferVision, Airdoc, VUNO and Lunit, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Lung Cancer Screening Software market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Lung Cancer Screening Software and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Lung Cancer Screening Software revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Lung Cancer Screening Software market.

Lung Cancer Screening Software Segment by Company

Siemens Healthineers

GE HealthCare

Philips Healthcare

Canon Medical Systems

United Imaging Healthcare

InferVision

Airdoc

VUNO

Lunit

Qure.ai

Riverain Technologies

Zebra Medical Vision

Arterys

Deepwise

EverFortune AI

Lung Cancer Screening Software Segment by Type

Cloud-Based

Web-Based

Lung Cancer Screening Software Segment by Application

Hospitals

Medical Examination Institutions

Public Health Screening

Others

Lung Cancer Screening Software Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Lung Cancer Screening Software status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Lung Cancer Screening Software key companies, revenue, market share, and recent developments.

3. To split the Lung Cancer Screening Software breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Lung Cancer Screening Software market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Lung Cancer Screening Software significant trends, drivers, influence factors in global and regions.

6. To analyze Lung Cancer Screening Software competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Lung Cancer Screening Software market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Lung Cancer Screening Software and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Lung Cancer Screening Software.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Lung Cancer Screening Software industry.

Chapter 3: Detailed analysis of Lung Cancer Screening Software company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Lung Cancer Screening Software in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Lung Cancer Screening Software in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Lung Cancer Screening Software Industry Trends Table 2. Lung Cancer Screening Software Industry Drivers Table 3. Lung Cancer Screening Software Industry Opportunities and Challenges Table 4. Lung Cancer Screening Software Industry Restraints Table 5. Global Lung Cancer Screening Software Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Lung Cancer Screening Software Revenue Share by Company (2021-2026) Table 7. Global Lung Cancer Screening Software Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Lung Cancer Screening Software Key Company Manufacturing Base & Headquarters Table 9. Global Lung Cancer Screening Software Company, Product Type & Application Table 10. Global Lung Cancer Screening Software Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Lung Cancer Screening Software by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Cloud-Based Table 15. Significant Companies of Web-Based Table 16. Global Lung Cancer Screening Software Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Lung Cancer Screening Software Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Lung Cancer Screening Software Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Lung Cancer Screening Software Sales Value Share by Type (2021-2026) Table 20. Global Lung Cancer Screening Software Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospitals Table 22. Significant Companies of Medical Examination Institutions Table 23. Significant Companies of Public Health Screening Table 24. Significant Companies of Others Table 25. Global Lung Cancer Screening Software Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Lung Cancer Screening Software Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Lung Cancer Screening Software Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Lung Cancer Screening Software Sales Value Share by Application (2021-2026) Table 29. Global Lung Cancer Screening Software Sales Value Share by Application (2027-2032) Table 30. Global Lung Cancer Screening Software Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Lung Cancer Screening Software Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Lung Cancer Screening Software Sales Value Share by Region (2021-2026) Table 33. Global Lung Cancer Screening Software Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Lung Cancer Screening Software Sales Value Share by Region (2027-2032) Table 35. Global Lung Cancer Screening Software Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Lung Cancer Screening Software Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Lung Cancer Screening Software Sales Value Market Share by Country (2021-2026) Table 38. Global Lung Cancer Screening Software Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Lung Cancer Screening Software Sales Value Market Share by Country (2027-2032) Table 40. Siemens Healthineers Company Information Table 41. Siemens Healthineers Business Overview Table 42. Siemens Healthineers Lung Cancer Screening Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Siemens Healthineers Lung Cancer Screening Software Product Portfolio Table 44. Siemens Healthineers Recent Development Table 45. GE HealthCare Company Information Table 46. GE HealthCare Business Overview Table 47. GE HealthCare Lung Cancer Screening Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. GE HealthCare Lung Cancer Screening Software Product Portfolio Table 49. GE HealthCare Recent Development Table 50. Philips Healthcare Company Information Table 51. Philips Healthcare Business Overview Table 52. Philips Healthcare Lung Cancer Screening Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Philips Healthcare Lung Cancer Screening Software Product Portfolio Table 54. Philips Healthcare Recent Development Table 55. Canon Medical Systems Company Information Table 56. Canon Medical Systems Business Overview Table 57. Canon Medical Systems Lung Cancer Screening Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Canon Medical Systems Lung Cancer Screening Software Product Portfolio Table 59. Canon Medical Systems Recent Development Table 60. United Imaging Healthcare Company Information Table 61. United Imaging Healthcare Business Overview Table 62. United Imaging Healthcare Lung Cancer Screening Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. United Imaging Healthcare Lung Cancer Screening Software Product Portfolio Table 64. United Imaging Healthcare Recent Development Table 65. InferVision Company Information Table 66. InferVision Business Overview Table 67. InferVision Lung Cancer Screening Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. InferVision Lung Cancer Screening Software Product Portfolio Table 69. InferVision Recent Development Table 70. Airdoc Company Information Table 71. Airdoc Business Overview Table 72. Airdoc Lung Cancer Screening Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Airdoc Lung Cancer Screening Software Product Portfolio Table 74. Airdoc Recent Development Table 75. VUNO Company Information Table 76. VUNO Business Overview Table 77. VUNO Lung Cancer Screening Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. VUNO Lung Cancer Screening Software Product Portfolio Table 79. VUNO Recent Development Table 80. Lunit Company Information Table 81. Lunit Business Overview Table 82. Lunit Lung Cancer Screening Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Lunit Lung Cancer Screening Software Product Portfolio Table 84. Lunit Recent Development Table 85. Qure.ai Company Information Table 86. Qure.ai Business Overview Table 87. Qure.ai Lung Cancer Screening Software Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Qure.ai Lung Cancer Screening Software Product Portfolio Table 89. Qure.ai Recent Development Table 90. Riverain Technologies Company Information Table 91. Riverain Technologies Business Overview Table 92. Riverain Technologies Lung Cancer Screening Software Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 93. Riverain Technologies Lung Cancer Screening Software Product Portfolio Table 94. Riverain Technologies Recent Development Table 95. Zebra Medical Vision Company Information Table 96. Zebra Medical Vision Business Overview Table 97. Zebra Medical Vision Lung Cancer Screening Software Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 98. Zebra Medical Vision Lung Cancer Screening Software Product Portfolio Table 99. Zebra Medical Vision Recent Development Table 100. Arterys Company Information Table 101. Arterys Business Overview Table 102. Arterys Lung Cancer Screening Software Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 103. Arterys Lung Cancer Screening Software Product Portfolio Table 104. Arterys Recent Development Table 105. Deepwise Company Information Table 106. Deepwise Business Overview Table 107. Deepwise Lung Cancer Screening Software Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 108. Deepwise Lung Cancer Screening Software Product Portfolio Table 109. Deepwise Recent Development Table 110. EverFortune AI Company Information Table 111. EverFortune AI Business Overview Table 112. EverFortune AI Lung Cancer Screening Software Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 113. EverFortune AI Lung Cancer Screening Software Product Portfolio Table 114. EverFortune AI Recent Development Table 115. Research Programs/Design for This Report Table 116. Authors List of This Report Table 117. Secondary Sources Table 118. Primary Sources List of Figures Figure 1. Lung Cancer Screening Software Product Image Figure 2. Global Lung Cancer Screening Software Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Lung Cancer Screening Software Market Size (2021-2032) & (US$ Million) Figure 4. Global Lung Cancer Screening Software Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Cloud-Based Image Figure 8. Web-Based Image Figure 9. Global Lung Cancer Screening Software Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Lung Cancer Screening Software Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Lung Cancer Screening Software Sales Value Share by Type (2021-2032) Figure 12. Hospitals Image Figure 13. Medical Examination Institutions Image Figure 14. Public Health Screening Image Figure 15. Others Image Figure 16. Global Lung Cancer Screening Software Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Lung Cancer Screening Software Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Lung Cancer Screening Software Sales Value Share by Application (2021-2032) Figure 19. Global Lung Cancer Screening Software Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Lung Cancer Screening Software Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Lung Cancer Screening Software Sales Value (2021-2032) & (US$ Million) Figure 22. North America Lung Cancer Screening Software Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Lung Cancer Screening Software Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Lung Cancer Screening Software Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Lung Cancer Screening Software Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Lung Cancer Screening Software Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Lung Cancer Screening Software Sales Value (2021-2032) & (US$ Million) Figure 28. South America Lung Cancer Screening Software Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Lung Cancer Screening Software Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Lung Cancer Screening Software Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Lung Cancer Screening Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Lung Cancer Screening Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Lung Cancer Screening Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Lung Cancer Screening Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Lung Cancer Screening Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Lung Cancer Screening Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Lung Cancer Screening Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Lung Cancer Screening Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Lung Cancer Screening Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Lung Cancer Screening Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Lung Cancer Screening Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Lung Cancer Screening Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Lung Cancer Screening Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Lung Cancer Screening Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Lung Cancer Screening Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Lung Cancer Screening Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Lung Cancer Screening Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Lung Cancer Screening Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Lung Cancer Screening Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Lung Cancer Screening Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Lung Cancer Screening Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Lung Cancer Screening Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Lung Cancer Screening Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Lung Cancer Screening Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Lung Cancer Screening Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Lung Cancer Screening Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Lung Cancer Screening Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Lung Cancer Screening Software Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Cloud-Based
  • Web-Based
Applications
  • Hospitals
  • Medical Examination Institutions
  • Public Health Screening
  • Others
Companies covered
  • Siemens Healthineers
  • GE HealthCare
  • Philips Healthcare
  • Canon Medical Systems
  • United Imaging Healthcare
  • InferVision
  • Airdoc
  • VUNO
  • Lunit
  • Qure.ai
  • Riverain Technologies
  • Zebra Medical Vision
  • Arterys
  • Deepwise
  • EverFortune AI

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Lung Cancer Screening Software Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Lung Cancer Screening Software Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Lung Cancer Screening Software Market Dynamics
  1. 2.1 Lung Cancer Screening Software Industry Trends
  2. 2.2 Lung Cancer Screening Software Industry Drivers
  3. 2.3 Lung Cancer Screening Software Industry Opportunities and Challenges
  4. 2.4 Lung Cancer Screening Software Industry Restraints
3 Lung Cancer Screening Software Market by Company
  1. 3.1 Global Lung Cancer Screening Software Company Revenue Ranking in 2025
  2. 3.2 Global Lung Cancer Screening Software Revenue by Company (2021-2026)
  3. 3.3 Global Lung Cancer Screening Software Company Ranking (2024-2026)
  4. 3.4 Global Lung Cancer Screening Software Company Manufacturing Base and Headquarters
  5. 3.5 Global Lung Cancer Screening Software Company Product Type and Application
  6. 3.6 Global Lung Cancer Screening Software Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Lung Cancer Screening Software Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Lung Cancer Screening Software Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Lung Cancer Screening Software Market by Type
  1. 4.1 Lung Cancer Screening Software Type Introduction
  2. 4.1.1 Cloud-Based
  3. 4.1.2 Web-Based
  4. 4.2 Global Lung Cancer Screening Software Sales Value by Type
  5. 4.2.1 Global Lung Cancer Screening Software Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Lung Cancer Screening Software Sales Value by Type (2021-2032)
  7. 4.2.3 Global Lung Cancer Screening Software Sales Value Share by Type (2021-2032)
5 Lung Cancer Screening Software Market by Application
  1. 5.1 Lung Cancer Screening Software Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Medical Examination Institutions
  4. 5.1.3 Public Health Screening
  5. 5.1.4 Others
  6. 5.2 Global Lung Cancer Screening Software Sales Value by Application
  7. 5.2.1 Global Lung Cancer Screening Software Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Lung Cancer Screening Software Sales Value by Application (2021-2032)
  9. 5.2.3 Global Lung Cancer Screening Software Sales Value Share by Application (2021-2032)
6 Lung Cancer Screening Software Regional Value Analysis
  1. 6.1 Global Lung Cancer Screening Software Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Lung Cancer Screening Software Sales Value by Region (2021-2032)
  3. 6.2.1 Global Lung Cancer Screening Software Sales Value by Region: 2021-2026
  4. 6.2.2 Global Lung Cancer Screening Software Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Lung Cancer Screening Software Sales Value (2021-2032)
  7. 6.3.2 North America Lung Cancer Screening Software Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Lung Cancer Screening Software Sales Value (2021-2032)
  10. 6.4.2 Europe Lung Cancer Screening Software Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Lung Cancer Screening Software Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Lung Cancer Screening Software Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Lung Cancer Screening Software Sales Value (2021-2032)
  16. 6.6.2 South America Lung Cancer Screening Software Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Lung Cancer Screening Software Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Lung Cancer Screening Software Sales Value Share by Country, 2025 VS 2032
7 Lung Cancer Screening Software Country-level Value Analysis
  1. 7.1 Global Lung Cancer Screening Software Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Lung Cancer Screening Software Sales Value by Country (2021-2032)
  3. 7.2.1 Global Lung Cancer Screening Software Sales Value by Country (2021-2026)
  4. 7.2.2 Global Lung Cancer Screening Software Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Lung Cancer Screening Software Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Lung Cancer Screening Software Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Lung Cancer Screening Software Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Lung Cancer Screening Software Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Lung Cancer Screening Software Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Lung Cancer Screening Software Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Lung Cancer Screening Software Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Lung Cancer Screening Software Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Lung Cancer Screening Software Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Lung Cancer Screening Software Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Lung Cancer Screening Software Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Lung Cancer Screening Software Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Lung Cancer Screening Software Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Lung Cancer Screening Software Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Lung Cancer Screening Software Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Lung Cancer Screening Software Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Lung Cancer Screening Software Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Lung Cancer Screening Software Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Lung Cancer Screening Software Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Lung Cancer Screening Software Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Lung Cancer Screening Software Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Lung Cancer Screening Software Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Lung Cancer Screening Software Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Lung Cancer Screening Software Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Lung Cancer Screening Software Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Lung Cancer Screening Software Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Lung Cancer Screening Software Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Lung Cancer Screening Software Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Lung Cancer Screening Software Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Lung Cancer Screening Software Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Siemens Healthineers
  2. 8.1.1 Siemens Healthineers Company Information
  3. 8.1.2 Siemens Healthineers Business Overview
  4. 8.1.3 Siemens Healthineers Lung Cancer Screening Software Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Siemens Healthineers Lung Cancer Screening Software Product Portfolio
  6. 8.1.5 Siemens Healthineers Recent Developments
  7. 8.2 GE HealthCare
  8. 8.2.1 GE HealthCare Company Information
  9. 8.2.2 GE HealthCare Business Overview
  10. 8.2.3 GE HealthCare Lung Cancer Screening Software Revenue and Gross Margin (2021-2026)
  11. 8.2.4 GE HealthCare Lung Cancer Screening Software Product Portfolio
  12. 8.2.5 GE HealthCare Recent Developments
  13. 8.3 Philips Healthcare
  14. 8.3.1 Philips Healthcare Company Information
  15. 8.3.2 Philips Healthcare Business Overview
  16. 8.3.3 Philips Healthcare Lung Cancer Screening Software Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Philips Healthcare Lung Cancer Screening Software Product Portfolio
  18. 8.3.5 Philips Healthcare Recent Developments
  19. 8.4 Canon Medical Systems
  20. 8.4.1 Canon Medical Systems Company Information
  21. 8.4.2 Canon Medical Systems Business Overview
  22. 8.4.3 Canon Medical Systems Lung Cancer Screening Software Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Canon Medical Systems Lung Cancer Screening Software Product Portfolio
  24. 8.4.5 Canon Medical Systems Recent Developments
  25. 8.5 United Imaging Healthcare
  26. 8.5.1 United Imaging Healthcare Company Information
  27. 8.5.2 United Imaging Healthcare Business Overview
  28. 8.5.3 United Imaging Healthcare Lung Cancer Screening Software Revenue and Gross Margin (2021-2026)
  29. 8.5.4 United Imaging Healthcare Lung Cancer Screening Software Product Portfolio
  30. 8.5.5 United Imaging Healthcare Recent Developments
  31. 8.6 InferVision
  32. 8.6.1 InferVision Company Information
  33. 8.6.2 InferVision Business Overview
  34. 8.6.3 InferVision Lung Cancer Screening Software Revenue and Gross Margin (2021-2026)
  35. 8.6.4 InferVision Lung Cancer Screening Software Product Portfolio
  36. 8.6.5 InferVision Recent Developments
  37. 8.7 Airdoc
  38. 8.7.1 Airdoc Company Information
  39. 8.7.2 Airdoc Business Overview
  40. 8.7.3 Airdoc Lung Cancer Screening Software Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Airdoc Lung Cancer Screening Software Product Portfolio
  42. 8.7.5 Airdoc Recent Developments
  43. 8.8 VUNO
  44. 8.8.1 VUNO Company Information
  45. 8.8.2 VUNO Business Overview
  46. 8.8.3 VUNO Lung Cancer Screening Software Revenue and Gross Margin (2021-2026)
  47. 8.8.4 VUNO Lung Cancer Screening Software Product Portfolio
  48. 8.8.5 VUNO Recent Developments
  49. 8.9 Lunit
  50. 8.9.1 Lunit Company Information
  51. 8.9.2 Lunit Business Overview
  52. 8.9.3 Lunit Lung Cancer Screening Software Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Lunit Lung Cancer Screening Software Product Portfolio
  54. 8.9.5 Lunit Recent Developments
  55. 8.10 Qure.ai
  56. 8.10.1 Qure.ai Company Information
  57. 8.10.2 Qure.ai Business Overview
  58. 8.10.3 Qure.ai Lung Cancer Screening Software Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Qure.ai Lung Cancer Screening Software Product Portfolio
  60. 8.10.5 Qure.ai Recent Developments
  61. 8.11 Riverain Technologies
  62. 8.11.1 Riverain Technologies Company Information
  63. 8.11.2 Riverain Technologies Business Overview
  64. 8.11.3 Riverain Technologies Lung Cancer Screening Software Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Riverain Technologies Lung Cancer Screening Software Product Portfolio
  66. 8.11.5 Riverain Technologies Recent Developments
  67. 8.12 Zebra Medical Vision
  68. 8.12.1 Zebra Medical Vision Company Information
  69. 8.12.2 Zebra Medical Vision Business Overview
  70. 8.12.3 Zebra Medical Vision Lung Cancer Screening Software Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Zebra Medical Vision Lung Cancer Screening Software Product Portfolio
  72. 8.12.5 Zebra Medical Vision Recent Developments
  73. 8.13 Arterys
  74. 8.13.1 Arterys Company Information
  75. 8.13.2 Arterys Business Overview
  76. 8.13.3 Arterys Lung Cancer Screening Software Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Arterys Lung Cancer Screening Software Product Portfolio
  78. 8.13.5 Arterys Recent Developments
  79. 8.14 Deepwise
  80. 8.14.1 Deepwise Company Information
  81. 8.14.2 Deepwise Business Overview
  82. 8.14.3 Deepwise Lung Cancer Screening Software Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Deepwise Lung Cancer Screening Software Product Portfolio
  84. 8.14.5 Deepwise Recent Developments
  85. 8.15 EverFortune AI
  86. 8.15.1 EverFortune AI Company Information
  87. 8.15.2 EverFortune AI Business Overview
  88. 8.15.3 EverFortune AI Lung Cancer Screening Software Revenue and Gross Margin (2021-2026)
  89. 8.15.4 EverFortune AI Lung Cancer Screening Software Product Portfolio
  90. 8.15.5 EverFortune AI Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst